XM does not provide services to residents of the United States of America.

Swiss EMS Chemie H1 sales drop 8.1%, cuts 2024 sales guidance



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Swiss EMS Chemie H1 sales drop 8.1%, cuts 2024 sales guidance</title></head><body>

Adds analyst comments in paragraphs 3, 8, 10, share move in paragraph 2

July 12 (Reuters) -Swiss nylon manufacturer EMS Chemie EMSN.S cut its 2024 sales guidance on Friday after reporting weaker-than-expected first-half sales, citing currency effects as the Swiss franc strengthened.

The stock slumped 6.5% as of 0750 GMT, heading for its worst day since April.

Net sales in the first half of the year declined 8.1% to 1.09 billion Swiss francs ($1.22 billion), EMS said, which, according to Vontobel analyst Sibylle Bischofberger did not meet consensus estimates.

The company said it now expects its 2024 net sales to fall slightly, after previously forecasting net sales in line with the 2023 figure of 2.19 billion Swiss francs.

EMS Chemie forecast the economic environment would continue to be difficult in 2024, adding there was no sign of any growth impulse in global manufacturing.

"New political regulations and penal customs duties are also unsettling consumer confidence and hampering companies' investment decisions," the company said in a statement.

The mood in the European chemical industry remains cautious as the sector has long been suffering from weak demand and high production costs.

Bischofberger said the company's specialty product portfolio is less affected by the challenging situation, but added that EMS Chemie "cannot escape market developments".

The company reaffirmed its full-year earnings before interest and tax (EBIT) outlook and still sees a figure slightly above previous year's 493 million francs.

Analysts said EMS Chemie's margins had improved significantly, helped by higher volumes and after expanding in Asia, America and Europe.

EMS Chemie kicked off the earnings reporting season for European chemical makers, with peers such as Clariant CLN.S, K+S SDFGn.DE and Givaudan GIVN.S set to report their quarterly results in the coming weeks.


($1 = 0.8958 Swiss francs)



($1 = 0.8955 Swiss francs)



Reporting by Marta Frackowiak and Bartosz Dabrowski in Gdansk
Editing by Ludwig Burger and Sharon Singleton

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.